Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by RMR Wealth Builders

RMR Wealth Builders raised its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 9.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,239 shares of the pharmaceutical company’s stock after buying an additional 351 shares during the quarter. RMR Wealth Builders’ holdings in Vertex Pharmaceuticals were worth $1,707,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of VRTX. Northwest Investment Counselors LLC acquired a new position in Vertex Pharmaceuticals in the 3rd quarter valued at $25,000. Highline Wealth Partners LLC purchased a new position in Vertex Pharmaceuticals during the third quarter worth about $27,000. Dunhill Financial LLC raised its holdings in Vertex Pharmaceuticals by 70.6% in the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 24 shares during the period. Legacy Investment Solutions LLC acquired a new position in Vertex Pharmaceuticals during the third quarter valued at approximately $33,000. Finally, Truvestments Capital LLC purchased a new stake in Vertex Pharmaceuticals during the third quarter worth approximately $35,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on VRTX shares. Royal Bank of Canada lifted their target price on shares of Vertex Pharmaceuticals from $437.00 to $451.00 and gave the company a “sector perform” rating in a report on Tuesday, November 5th. Raymond James reissued a “market perform” rating on shares of Vertex Pharmaceuticals in a research report on Thursday, October 10th. Truist Financial decreased their target price on Vertex Pharmaceuticals from $550.00 to $460.00 and set a “buy” rating for the company in a research report on Monday, December 23rd. Morgan Stanley boosted their price target on Vertex Pharmaceuticals from $473.00 to $476.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. Finally, UBS Group raised their price target on shares of Vertex Pharmaceuticals from $562.00 to $586.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Vertex Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $490.38.

Vertex Pharmaceuticals Stock Up 3.1 %

Shares of NASDAQ VRTX opened at $424.26 on Thursday. The firm’s 50-day simple moving average is $445.93 and its 200 day simple moving average is $467.13. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $377.85 and a fifty-two week high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, beating analysts’ consensus estimates of $3.61 by $0.77. The business had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.69 billion. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The business’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same quarter last year, the business earned $3.67 earnings per share. On average, equities research analysts predict that Vertex Pharmaceuticals Incorporated will post -1.9 EPS for the current year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.